• Home
  • Chongqing Zhifei Biological Products Co., Ltd.
16
Jun
2027
National Exhibition and Convention Center
16 Jun 2027 - 18 Jun 2027
stand 72B22
Book a meeting

Chongqing Zhifei Biological Products Co., Ltd.

About Chongqing Zhifei Biological Products Co., Ltd.

Chongqing Zhifei Biological Products Co., Ltd. is the largest listed vaccine company in China，which has its presence in biological product industry in 2002.The Company achieved an operating income of RMB38.3 billion In  2022 with the support of its nearly 7000 employees.As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use. Our research channels cover many indications extensively: like COVID-19, tuberculosis, meningitis, etc.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI & PMEC China 2027

    CPHI & PMEC China 2027

    National Exhibition and Convention Center
    16 Jun 2027 - 18 Jun 2027
    stand 72B22
  • Country/Region:
    China
  • On CPHI since:
    2015
  • Employees:
    5000+
Company types
Manufacturer/Innovator
Contact info
Show contact info Hide contact info

Products from Chongqing Zhifei Biological Products Co., Ltd. (4)

  • Recombinant Mycobacterium Tuberculosis Fusion Protein

    Product Recombinant Mycobacterium Tuberculosis Fusion Protein

    C-TST is a new diagnose method to detect Mtb infectionfor,which uses antigen-specific (ESAT6 & CFP10) immune response, same with the principle of action used in IGRAs.(1）Suitable for Large Scale LTBI Screening； 
    (2）Non Cross-React with BCG Vaccine; 
    (3）WHO Guideline Recommended;  q...
  • Meningococcal Polysaccharide Vaccine

    Product Meningococcal Polysaccharide Vaccine

    Chongqing zhifei biological products co., ltd offers a wide range of products which includes meningococcal polysaccharide vaccine. Function and use: it can be used to prevent epidemic cerebrospinal meningitis caused by meningococcus group a, c, y, and w135 infection. Contact us for more information.
  • 23-valent Pneumococcal PolysaccharideVaccine

    Product 23-valent Pneumococcal PolysaccharideVaccine

    Covers a wider range of pneumococcal serotypesMore economical for low-and middle-income countries
    Patented process
    Great immunogenicity and safety
    Prefilled Syringe

  • Quadrivalent Influenza Vaccine

    Product Quadrivalent Influenza Vaccine

    Quadrivalent Influenza Vaccine

Chongqing Zhifei Biological Products Co., Ltd. Resources (1)